Cecilie Hoeeg

Mrs. Cecilie Hoeeg

Rigshospitalet
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2021 in Gels
Verified
Journal Article
Open access
PDF file
Cecilie HoeegCecilie Hoeeg
Cecilie Hoeeg
Alireza Dolatshahi-PirouzAlireza Dolatshahi-Pirouz
Alireza Dolatshahi-Pirouz
Bjarke FollinBjarke Follin
Bjarke Follin
Cell therapy has the potential to regenerate cardiac tissue and treat a variety of cardiac diseases which are currently without effective treatment. This novel approach to treatment has demonstrated clinical efficiency, despite low retention of the cell products in the heart. It has been shown that improving retention often leads to improved functional outcome. A feasible method of improving cell graft retention is administration of injectable hydrogels. Over the last decade, a variety of injectable hydrogels have been investigated preclinically for their potential to improve the effects of cardiac cell therapy. These hydrogels are created with different polymers, properties, and additional functional motifs and differ in their approaches for encapsulating different cell types. Only one combinational therapy has been tested in a clinical randomized controlled trial. In this review, the latest research on the potential of injectable hydrogels for delivery of cell therapy is discussed, together with potential roadblocks for clinical translation and recommendations for future explorations to facilitate future translation.

1 January 2020 in Methods
Verified
Journal Article
Closed access
Simone PorsborgSimone Porsborg
Simone Porsborg
AHAnne Cathrine Hansen
Anne Cathrine Hansen
LJLonnie Johansen
Lonnie Johansen
KLKaya Lund
Kaya Lund
Cecilie HoeegCecilie Hoeeg
Cecilie Hoeeg
Cristian Pablo PennisiCristian Pablo Pennisi
Cristian Pablo Pennisi

5 December 2020 in Biomedicines
Verified
Journal Article
Open access
PDF file
Cecilie HoeegCecilie Hoeeg
Cecilie Hoeeg
SFSabina Frljak
Sabina Frljak
AQAbbas Ali Qayyum
Abbas Ali Qayyum
BVBojan Vrtovec
Bojan Vrtovec
JKJens Kastrup
Jens Kastrup
Bjarke FollinBjarke Follin
Bjarke Follin
Non-ischemic dilated cardiomyopathy (NIDCM) constitutes one of the most common causes to non-ischemic heart failure. Despite treatment, the disease often progresses, causing severe morbidity and mortality, making novel treatment strategies necessary. Due to the regenerative actions of mesenchymal stem cells (MSCs), they have been proposed as a treatment for NIDCM. This systematic review aims to evaluate efficacy and mode of action (MoA) of MSC-based therapies in NIDCM. A systematic literature search was conducted in Medline (Pubmed) and Embase. A total of 27 studies were included (3 clinical trials and 24 preclinical studies). MSCs from different tissues and routes of delivery were reported, with bone marrow-derived MSCs and direct intramyocardial injections being the most frequent. All included clinical trials and 22 preclinical trials reported an improvement in cardiac function following MSC treatment. Furthermore, preclinical studies demonstrated alterations in tissue structure, gene, and protein expression patterns, primarily related to fibrosis and angiogenesis. Consequently, MSC treatment can improve cardiac function in NIDCM patients. The MoA underlying this effect involves anti-fibrosis, angiogenesis, immunomodulation, and anti-apoptosis, though these processes seem to be interdependent. These encouraging results calls for larger confirmatory clinical studies, as well as preclinical studies utilizing unbiased investigation of the potential MoA.

Verified
Journal Article
Open access
PDF file
Bjarke FollinBjarke Follin
Bjarke Follin
Cecilie HoeegCecilie Hoeeg
Cecilie Hoeeg
LHLisbeth D. Højgaard
Lisbeth D. Højgaard
MJMorten Juhl
Morten Juhl
KLKaya B. Lund
Kaya B. Lund
Andreas KjaerAndreas Kjaer
Andreas Kjaer
Mesenchymal stromal cells have proven capable of improving cardiac pump function in patients with chronic heart failure, yet little is known about their mode of action. The aim of the study was to investigate the short-term effect of cryopreserved allogeneic rat adipose tissue-derived stromal cells (ASC) on cardiac composition, cellular subpopulations, and gene transcription in a rat model of chronic ischemic cardiomyopathy (ICM). Myocardial infarction (MI) was induced by permanent ligation of the left anterior descending coronary artery. After 6 weeks, the rats were treated with ASCs, saline, or no injection, using echo-guided trans-thoracic intramyocardial injections. The cardiac tissue was subsequently collected for analysis of cellular subpopulations and gene transcription 3 and 7 days after treatment. At day 3, an upregulation of genes associated with angiogenesis were present in the ASC group. On day 7, increases in CCR2+ and CD38+ macrophages (p = 0.047 and p = 0.021), as well as in the CD4/CD8 lymphocyte ratio (p = 0.021), were found in the ASC group compared to the saline group. This was supported by an upregulation of genes associated with monocytes/macrophages. In conclusion, ASC treatment initiated an immune response involving monocytes/macrophages and T-cells and induced a gene expression pattern associated with angiogenesis and monocyte/macrophage differentiation.

11 January 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
Bjarke FollinBjarke Follin
Bjarke Follin
Cecilie HoeegCecilie Hoeeg
Cecilie Hoeeg
IHIngrid Hunter
Ingrid Hunter
SBSimon Bentsen
Simon Bentsen
MJMorten Juhl
Morten Juhl
Andreas KjaerAndreas Kjaer
Andreas Kjaer
An increasing number of patients are living with chronic ischemic cardiomyopathy (ICM) and/or heart failure. Treatment options and prognostic tools are lacking for many of these patients. Our aim was to investigate the prognostic value of imaging angiogenesis and macrophage activation via positron emission tomography (PET) in terms of functional improvement after cell therapy. Myocardial infarction was induced in rats. Animals were scanned with [18F]FDG PET and echocardiography after four weeks and randomized to allogeneic adipose tissue-derived stromal cells (ASCs, n = 18) or saline (n = 9). Angiogenesis and macrophage activation were assessed before and after treatment by [68Ga]Ga-RGD and [64Cu]Cu-DOTATATE. There was no overall effect of the treatment. Rats that improved left ventricular ejection fraction (LVEF) had higher uptake of both [68Ga]Ga-RGD and [64Cu]Cu-DOTATATE at follow-up (p = 0.006 and p = 0.008, respectively). The uptake of the two tracers correlated with each other (r = 0.683, p = 0.003 pre-treatment and r = 0.666, p = 0.004 post-treatment). SUVmax at follow-up could predict improvement in LVEF (p = 0.016 for [68Ga]Ga-RGD and p = 0.045 for [64Cu]Cu-DOTATATE). High uptake of [68Ga]Ga-RGD and [64Cu]Cu-DOTATATE PET after injection of ASCs or saline preceded improvement in LVEF. The use of these tracers could improve the monitoring of heart failure patients in treatment.

11 February 2021 in Current Protocols
Verified
Journal Article
Open access
PDF file
Cecilie HoeegCecilie Hoeeg
Cecilie Hoeeg
LRLars Ringgaard
Lars Ringgaard
ECEsben Christensen
Esben Christensen
Bjarke FollinBjarke Follin
Bjarke Follin
SBSimon Bentsen
Simon Bentsen
Andreas KjaerAndreas Kjaer
Andreas Kjaer
Angiogenesis is involved in regeneration of cardiac tissue following acute myocardial infarction (MI), a disease often investigated in rat models. Therefore, the ability to thoroughly evaluate the angiogenic response following experimentally induced MI in rats, and distinguish it from inflammation, is desired. This would enable evaluation of the angiogenic potential of new therapeutics and improve knowledge on MI pathophysiology. Due to the complex response to MI involving multiple cell types and the limited selection of rat‐specific antibodies, careful optimization is crucial to capture this complexity. Here, we present an 8‐color flow cytometry‐based multicolor panel that will enable quantification of the ongoing angiogenic response as well as characterize the cells involved. A detailed description of tissue preparation, immunostaining, and gating strategy is provided. © 2021 Wiley Periodicals LLC.This article was corrected on 26 July 2022. See the end of the full text for details.Basic Protocol: Cardiac tissue preparation and staining to investigate the ongoing angiogenic response in rat cardiac tissue following myocardial infarctionSupport Protocol: Titration of all antibodies in the presented panel